NICE backs use of new treatment for multiple myeloma
Sanofi’s Sarclisa gets the final green light for use by the NHS with funding from the CDF
Read More
Tag: CDF
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Read More
NICE green light for Roche’s Rozlytrek
The drug targets all solid tumours with the NTRK gene fusions
Read More
NICE issues final guidance on NHS use of Bayer’s Vitrakvi
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read More
NICE backs NHS use of Bayer’s Vitrakvi via the CDF
The drug was initially considered too expensive but its cost to the NHS has been lowered
Read More
Ibrance given NICE green light in breast cancer
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
Read More
NICE approves CDF funding for Sanofi’s Libtayo
Around 560 patients per year with cutaneous squamous cell carcinoma are thought to be eligible for treatment with the drug in England
Read More
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
Read More
NICE green light for Keytruda in melanoma setting
NICE has given a green light for use of MSD’s Keytruda on the NHS to treat some patients with melanoma, with funding to come from the Cancer Drugs Fund.
Read More
Gilead strikes deal with NHS England on Yescarta access
Gilead has struck a deal with NHS England that allows some adults with lymphoma access to its “game-changing” CAR-T therapy Yescarta.
Read More
DH moves to ensure equal access to cancer drugs in NI
The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new medicines for cancers and other conditions.
Read More
NICE backing for Keytruda in classical Hodgkin lymphoma
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
